Novel Plasma Proteins Associated With Alzheimer’s Disease Risk in APOE ε4 Carriers and Non-carriers
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background Whether plasma protein associations with Alzheimer’s disease (AD) differ by genetic risk remains unclear. Methods We studied 18,212 UK Biobank participants aged ≥ 60 years with Olink Explore 3072 proteomic data, APOE genotypes, and AD polygenic risk scores. Protein-by-genetic risk interactions were screened, followed by genetic risk-stratified association and mediation analyses in Cox models. Results During 12.8 years of follow-up, 374 participants developed AD. APOE ε4 carriers had higher AD risk than non-carriers (HR = 7.79 [6.18–9.81]), with the greatest risk among ε4 homozygotes (HR = 17.73 [13.36–23.51]). Stratified analyses identified AD-associated proteins among APOE ε4 non-carriers (n = 85), ε4 carriers (n = 10), and low-, intermediate-, and high-AD-PRS groups (n = 10, 1, and 2, respectively), including 94 newly identified proteins. APOE protein, MENT, and GFAP mediated 34.49%, 25.01%, and 11.47% of the APOE ε4-AD association. Conclusions Genetic risk stratification revealed heterogeneous protein-AD associations and genotype-dependent proteomic pathways.
